Pre-Clinical Research
Filter News
Found 9,187 articles
-
Data from a Phase III trial of apraglutide for a type of short bowel syndrome with intestinal failure is expected by the end of the year. It is also in a Phase II study for acute graft-versus-host disease. -
More than $5 billion poured into the longevity space in 2022, and experts say the science is now primed to make a real difference in extending human healthspan. -
Microbot Medical Achieved 100% Success Rate for LIBERTY in Extensive Pre-Clinical Animal Study Performed by Leading European Physicians
5/22/2023
Microbot Medical Inc., the developer of the LIBERTY® Surgical Robotic System, the first single-use endovascular robotic system, announced a highly successful extended joint pre- clinical animal study held at a leading European-based research lab.
-
NeuBase Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors™
5/22/2023
NeuBase Therapeutics, Inc. today announced a broad set of preclinical safety and efficiency data for its Stealth Editors development program that demonstrate the ability to achieve gene editing with a non-immunogenic system.
-
Terns Pharmaceuticals to Highlight New Preclinical Data for TERN-601 Program in Obesity at the American Diabetes Association’s 83rd Annual Scientific Sessions
5/22/2023
Terns Pharmaceuticals, Inc. announced that new preclinical data from a transgenic mouse model evaluating TERN-601, a novel oral GLP-1R agonist, has been accepted for poster presentation at the American Diabetes Association’s 83rd Annual Scientific Sessions taking place June 23-26, 2023 in San Diego, California.
-
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
5/21/2023
Pieris Pharmaceuticals, Inc. announced the presentation of preclinical data from the Company's inhaled connective tissue growth factor antagonist program, PRS-220, for idiopathic pulmonary fibrosis at the annual American Thoracic Society International Conference being held in Washington, D.C. May 19-24, 2023.
-
Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT
5/19/2023
Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced multiple clinical and preclinical updates from its portfolio of investigational hematopoietic stem cell (HSC) gene therapies in neurometabolic and neurodegenerative disorders.
-
Epic Bio Presents Preclinical Data on EPI-321 for Facioscapulohumeral Muscular Dystrophy at ASGCT 26th Annual Meeting
5/19/2023
Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, presented promising preclinical data supporting development of EPI-321 for the treatment of facioscapulohumeral muscular dystrophy.
-
Navrogen Announces Publication of NAV-001 Antibody-Drug Conjugate Development and Efficacy in Humoral Immunosuppressed Cancers
5/18/2023
Navrogen, Inc., a biopharmaceutical company specialized in developing therapies for cancer and immune-related disorders, announces today a publication describing new criteria for antibody-drug conjugate (ADC) development and preclinical efficacy of NAV-001 ADC against mesothelin-expressing tumor types.
-
Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells
5/18/2023
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) today announced pre-clinical data demonstrating that using INTASYL to silence TIGIT and CBL-B may be used to improve the anti-tumor response of NK cells, creating a more effective cell therapy for treating cancer.
-
Affinia Therapeutics Presents New Preclinical Data on Novel AAV Capsids for Skeletal Muscle, Cardiac Muscle, and CNS at the American Society of Gene & Cell Therapy 26TH Annual Meeting
5/18/2023
Affinia Therapeutics today announced the presentation of new preclinical data on novel AAV capsids for skeletal muscle, cardiac muscle, and central nervous system (CNS).
-
Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
5/18/2023
Adicet Bio, Inc. announced preclinical data highlighting ADI-270, an armored allogeneic “off-the-shelf” gamma delta CAR T cell therapy candidate targeting CD70+ cancers, at the 26th Annual Meeting of the American Society of Gene & Cell Therapy taking place from May 16-20, 2023, in Los Angeles, CA.
-
Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting
5/18/2023
Voyager Therapeutics, Inc. presented data validating the ability of novel capsids generated through its TRACER™ capsid discovery platform to consistently demonstrate desirable features such as improved blood-brain barrier penetration and increased transgene expression in multiple areas of the brain compared to conventional AAV capsids, as well as cross-species translation.
-
STRM.BIO Appoints Independent Director Dawn Bell, PharmD, to its Board
5/17/2023
STRM.BIO today announced the appointment of Dawn Bell , PharmD, to its Board of Directors.
-
Prime Medicine to Present New Preclinical Data Highlighting Broad Potential of Prime Editing Technology at ASGCT 26th Annual Meeting
5/17/2023
Prime Medicine, Inc. announced the presentation of new preclinical data that further demonstrated the potential of Prime Editing to correct the causative mutation of chronic granulomatous disease and preclinical data that showcased the potential application of the Prime Editing Assisted Site-Specific Integrase Gene Editing platform to generate multiplex-edited CAR-T cells for the treatment of certain cancers and immune diseases.
-
Siren Biotechnology Unveils Preclinical Data for Universal AAV Immuno-Gene Therapy™ for Cancer, a Novel Modality that Combines AAV Gene Therapy and Cytokine Immunotherapy
5/17/2023
Siren Biotechnology announced the presentation of preclinical data demonstrating the effect of a novel treatment for cancer, Universal AAV Immuno-Gene Therapy, which combines AAV gene therapy and cytokine immunotherapy into a single modality.
-
Skyline Therapeutics Brings Multiple Data Presentations to ASGCT 2023
5/17/2023
Skyline Therapeutics, an innovation-driven gene therapy company dedicated to developing unique and novel solutions to address unmet needs in rare and severe diseases, is showcasing multiple data presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting.
-
Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
5/16/2023
Abeona Therapeutics Inc. announced new data regarding three internally developed preclinical gene therapy product candidates from its adeno-associated virus ophthalmology program that will be presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy, taking place from May 16-20, 2023 in Los Angeles, CA.
-
Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
5/16/2023
Locanabio, Inc. announced the presentation of data from its lead vectorized snRNA exon skipping program, LBIO-115, in development for the treatment of Duchenne muscular dystrophy.
-
Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting
5/16/2023
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, will present positive preclinical data from studies of AVB-202, the company’s gene therapy candidate for the treatment of Friedreich’s Ataxia (FA).